Overview
Primary infiltrating lobular carcinoma (ILC) of the breast represents a distinct subtype of breast cancer, characterized by its unique histological features and clinical behavior compared to invasive ductal carcinoma (IDC). ILC often presents with lower mammographic density and can be more challenging to detect through conventional imaging modalities due to its infiltrative growth pattern and propensity for multicentric or multifocal involvement. Given its distinct characteristics, understanding the diagnostic and management nuances specific to ILC is crucial for optimizing patient outcomes. While significant advancements have been made in imaging techniques, particularly with the advent of gallium-68 fluoropropyl-1,2-iodohistamine (FAPI) PET/CT, the overall evidence base remains somewhat limited, necessitating further large-scale, multicenter studies to establish standardized protocols and clinical outcomes.
Diagnosis
Imaging Techniques
The diagnosis of primary infiltrating lobular carcinoma (ILC) often relies on a combination of mammography, ultrasound, and magnetic resonance imaging (MRI). However, these conventional imaging modalities can sometimes fall short in detecting ILC due to its subtle radiographic appearance and tendency towards multifocal or multicentric spread. Recent advancements in molecular imaging have highlighted the potential of gallium-68 FAPI PET/CT in enhancing the detection and characterization of ILC [PMID:41746977]. Studies have demonstrated that FAPI PET/CT exhibits higher tumor uptake and greater lesion conspicuity in ILC cases, offering improved sensitivity over traditional imaging methods [PMID:41746977]. This enhanced visibility is particularly beneficial in identifying multifocal or multicentric primary foci, which are more common in ILC compared to invasive ductal carcinoma (IDC). Additionally, FAPI PET/CT has shown increased detection of nodal involvement, a critical factor in staging and guiding treatment decisions [PMID:41746977]. In clinical practice, integrating FAPI PET/CT into the diagnostic workup can provide more comprehensive information, potentially leading to earlier and more accurate staging of ILC.
Limitations and Considerations
Despite the promising results from studies utilizing FAPI PET/CT, the evidence base remains relatively nascent, and broader validation across diverse patient populations is warranted. Conventional imaging techniques still play a foundational role in initial screening and diagnosis, with FAPI PET/CT serving as a complementary tool for more detailed assessment. Clinicians should consider the cost-effectiveness and availability of advanced imaging modalities when incorporating FAPI PET/CT into routine practice. Furthermore, while FAPI PET/CT shows promise, its integration into standard diagnostic protocols requires further investigation to establish definitive clinical guidelines and to understand long-term outcomes associated with its use in ILC management.
Management
Current Evidence and Challenges
The management of primary infiltrating lobular carcinoma (ILC) faces several challenges due to the limited availability of large, multicenter studies that provide standardized protocols and robust clinical outcome data. Current evidence is largely observational and fragmented, making it difficult to establish universally applicable treatment guidelines [PMID:41746977]. Treatment approaches for ILC often mirror those for invasive ductal carcinoma (IDC), including surgery, adjuvant therapies such as chemotherapy, hormonal therapy, and radiation, tailored based on tumor characteristics and patient factors. However, the unique biology of ILC, including its propensity for multicentricity and potential resistance to certain therapies, necessitates a nuanced approach. For instance, ILC tumors are often estrogen receptor (ER) positive, which typically guides the use of endocrine therapy, but variability in response necessitates careful patient selection and monitoring [PMID:41746977].
Multidisciplinary Approach
Given the complexities and variability in ILC, a multidisciplinary team approach is essential. This includes oncologists, surgeons, radiologists, and pathologists collaborating closely to tailor treatment plans that account for the specific characteristics of ILC, such as multifocal disease and potential nodal involvement identified through advanced imaging techniques like FAPI PET/CT. Regular reassessment and adaptive management strategies are crucial, as ILC can exhibit different biological behaviors compared to IDC, potentially influencing treatment efficacy and patient outcomes. Clinicians must remain vigilant and responsive to emerging evidence, integrating new diagnostic tools and treatment modalities as they become validated through larger clinical trials.
Future Directions
To address the current gaps in evidence, there is an urgent need for larger, multicenter studies that focus specifically on ILC. These studies should aim to elucidate optimal treatment strategies, long-term outcomes, and the role of advanced imaging techniques like FAPI PET/CT in routine clinical evaluation. Understanding the molecular underpinnings of ILC could also pave the way for personalized medicine approaches, potentially identifying biomarkers that predict response to specific therapies. Until such comprehensive data are available, clinicians must rely on a combination of established guidelines for breast cancer management, adapted with caution and informed by emerging evidence to optimize care for patients with ILC.
Key Recommendations
References
1 Usmani S, Burney IA, Ahmed N, Al Riyami K, Ahmad N, Gnanasegaran G et al.. Radiolabeled fibroblast activation protein inhibitor PET/computed tomography imaging in invasive lobular breast cancer: a narrative review and research agenda. Nuclear medicine communications 2026. link
1 papers cited of 3 indexed.